Mankind Pharma

Mankind Pharma CROIC

The Cash Return on Invested Capital (CROIC) of Mankind Pharma (MANKIND.NS) as of Nov 1, 2026 is 11.59 %. In the previous year, Cash Return on Invested Capital (CROIC) was 8.55 % — a change of 35.63% (higher).

CROIC

11.59 %

YoY

35.63%

Last updated:

Cash Return on Invested Capital (CROIC) of Mankind Pharma is 2026 11.59 % . Cash Return on Invested Capital (CROIC) of Mankind Pharma was 2025 8.55 % . It decreases by 35.63% higher compared to the previous year.

The Mankind Pharma CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2019
10.72 INR
Jan 1, 2020
23.26 INR
Jan 1, 2021
16.49 INR
Jan 1, 2022
-20.26 INR
Jan 1, 2023
12.90 INR
Jan 1, 2024
18.50 INR
Jan 1, 2025
8.55 INR
Jan 1, 2026
11.59 INR
The Mankind Pharma CROIC history
YEARCROICYoY
11.59 %+35.63%
8.55 %-53.79%
18.50 %+43.36%
12.90 %-163.69%
-20.26 %-222.81%
16.49 %-29.09%
23.26 %+116.93%
10.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mankind Pharma Stock analysis

What does Mankind Pharma do? Mankind Pharma Ltd develops, manufactures, and markets pharmaceutical formulations across therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, and respiratory treatments. The company's portfolio includes brands such as Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, and Monticop, targeting acute and chronic conditions. These products are sold to healthcare providers, hospitals, and pharmacies across India, serving patients in diverse medical needs. The firm generates revenue through the sale of prescription and over-the-counter pharmaceuticals, leveraging its extensive portfolio in multiple therapeutic segments. Mankind Pharma focuses on therapeutic areas like anti-diabetic, dermatology, gynecology, pain/analgesics, urology, ophthalmology, and antiviral treatments, with brands such as Glimestar for diabetes and Manforce (Rx) for sexual health. The company's consumer healthcare products complement its prescription offerings, expanding market reach. Revenue streams come from the direct sale of branded formulations to distributors and retail chains, with no mention of external partnerships or additional services beyond pharmaceutical manufacturing and marketing. The company's therapeutic portfolio spans anti-malarial, blood-related, hormones, antineoplastic, hepatoprotective, and parenteral treatments, supported by brands like Cefakind for infections and Zenflox for respiratory issues. Sales are driven by its diverse product range covering both prescription and consumer healthcare segments, with no indication of licensing agreements or third-party collaborations. Mankind Pharma's revenue model relies solely on the marketing and distribution of its own branded pharmaceutical products within India's healthcare ecosystem. Mankind Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mankind Pharma stock

Cash Return on Invested Capital (CROIC) of Mankind Pharma is 11.59 % in 2026.

Cash Return on Invested Capital (CROIC) of Mankind Pharma changed from 8.55 % to 11.59 %, representing a 35.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Mankind Pharma since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Mankind Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Mankind Pharma

All Key Metrics — Mankind Pharma